ONCY

Oncolytics Biotech Stock Analysis

AI Rating

Neutral
  • Quality2/10
  • Growth↓ 3/10
  • Value↓ 1/10
Oncolytics Biotech sales and earnings growth
ONCY Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -8.33%
  • FCF Y/Y↓ -3.92%
Oncolytics Biotech gross and profit margin trends
ONCY Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↑ -1280.02%
Oncolytics Biotech net debt vs free cash flow
ONCY Risk
Great
  • Debt / Equity↑ 7.3
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Oncolytics Biotech stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗